EWTX NASDAQ
Edgewise Therapeutics, Inc.
1W: -2.8%
1M: +1.1%
3M: +11.2%
YTD: +38.2%
1Y: +121.9%
3Y: +263.9%
5Y: +30.3%
$32.82
+1.39 (+4.42%)
Weekly Expected Move ±11.8%
$25
$29
$33
$37
$41
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$3.5B
52W Range12.15-39.96
Volume773,284
Avg Volume1,041,580
Beta0.25
Dividend—
Analyst Ratings
Company Info
CEOKevin Koch
Employees117
SectorHealthcare
IndustryBiotechnology
IPO Date2021-03-26
Websiteedgewisetx.com
3415 Colorado Avenue
Boulder, CO 80303
US
Boulder, CO 80303
US
303 735 8373
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Latest News
Edgewise Therapeutics GAAP EPS of -$0.46
Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications
Rockwell Automation Posts Upbeat Q2 Results, Joins EverQuote, DigitalOcean And Other Big Stocks Moving Higher On Tuesday
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Can Myqorzo Drive Growth for Cytokinetics Amid Competition?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Donovan Joanne M. | M-Exempt | 50,000 | $7.08 | 2026-05-05 |
| Donovan Joanne M. | M-Exempt | 50,000 | $7.08 | 2026-05-05 |
| Donovan Joanne M. | S-Sale | 50,000 | $38.57 | 2026-05-05 |
| Donovan Joanne M. | S-Sale | 5,230 | $31.29 | 2026-05-04 |
| Fox Jonathan C | A-Award | 339 | — | 2026-04-01 |